1.69 USD
↗ 0.05 (3.05%)AT CLOSE (11:59 AM EDT)
ProKidney Corp. Class A Ordinary Shares
PROKNASDAQ • USD
1.65
↘ 0.04 (2.60%)
POST MARKET (AS OF 07:56 PM EDT)
Post Market
AS OF 07:56 PM EDT
1.65
↘ 0.04 (2.60%)
Market: CLOSED
ProKidney Corp. Class A Ordinary Shares (PROK) trades at $1.69 per share. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9 and a bearish Death Cross on the long-term moving averages. On the valuation front, PROK trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Aug 10, 2026.
Open?$1.63
High?$1.70
Low?$1.63
Prev. Close?$1.64
Volume?1.2M
Avg. Volume?1.1M
VWAP?$1.66
Rel. Volume?1.10x
Bid / Ask
Bid?$1.62 × 2.0K
Ask?$1.67 × 300
Spread?$0.05
Midpoint?$1.65
Valuation & Ratios
Market Cap?346.8M
Shares Out?205.2M
Float?88.1M
Float %?42.9%
P/E Ratio?N/A
P/B Ratio?-0.34
EPS?-$0.35
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Employees
231
Market Cap
336.5M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2022-07-12
Address
2000 FRONTIS PLAZA BLVD.
WINSTON-SALEM, NC 27103
Phone: 336-999-7028
WINSTON-SALEM, NC 27103
Phone: 336-999-7028
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?2
Momentum?43
Short Sent.?14
Piotroski F-Score?0/9Weak
Altman Z-Score?-0.20Distress
Confidence?66%Moderate
Short InterestSqueeze Risk
Short % of Float?23.75%Squeeze Risk
Short Interest?20.9M
Days to Cover?15.8
Free Float88.1M
Avg Daily Volume1.3M
Settlement Date2026-07-15
Financial Health
Current Ratio?9.06Strong
Quick Ratio?9.06Strong
Cash Ratio?3.93Strong
Debt/Equity?-0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?-0.34CHEAP▾
S&P97
P/S?390.09HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-1.5CHEAP▾
S&P97
EV/Sales?275.47HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?7.1%FAIR▾
Peers50
S&P23
ROA?-24.7%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-150055000
Enterprise Value?$244.9M
Fundamentals ratios updated end of day